• Contact Us
  • Indexing
  • Submit Manuscript
  • Open Access
  • Journals
  • Home
  • ISSN: 2373-9436
    Early Online
    Volume 6, Issue 1
    Case Report
    Daniel Motola-Kuba, Ileana Mackinney-Novelo*, and Ricardo Fernandez-Ferreira
    Rhabdomyosarcoma is extremely rare in adults, but is the most common extra cranial solid tumor in children. Rhabdomyosarcoma in adults is a heterogeneous disease, with different form of presentation, histology, and prognosis and with difficulty in its treatment due to the rarity of the disease.
    Here we briefly review the literature on adult rhabdomyosarcoma and present the case of a 39-year-old man clinical presentation of dyspnea, chest pain and weight loss, with initial approach with imaging studies and a mediastinal biopsy in which malignant neoplasia poorly differentiated with mesenchymal and epithelial immunophenotype is reported. He started chemotherapy with Paclitaxel/Carboplatin in a three-week regimen. After 2 cycles of chemotherapy a re-evaluation computed axial tomography showed progressive disease and the biopsy reported Embrionary Rhabdomyosarcoma with immunochemistry positive for myo D-1 and myogenine. Metastasis was confirmed at the diaphragm, retroperitoneal and central nervous system levels. 2nd line chemotherapy regimen with Vincristine, Doxorubicin and cyclophosphamide were initiated.
    Research Article
    Sunila Hussain*, Rakia Sahaf, Muhammad Rashid Siraj, Fakeha Rehman, Sameer Anjum, Nida Ali, Ayesha Saeed, Ihtesham-ud-Din Qureshi, and Nadia Naseem
    Extracellular matrix metalloproteinase inducer expression has been focus of research for variety of neoplasm's owing to its potential role played in invasion, angiogenesis and metastasis through interactions with other molecules.
    This study was designed to determine the immunohistochemical expression of EMMPRIN in benign and malignant salivary glands tumors in local population.
    This descriptive study was conducted at the Department of Morbid Anatomy and Histopathology/ Oral Pathology, University of Health Sciences Lahore, Pakistan. Biopsies and detailed clinical data of 85 cases of salivary gland neoplasm's (25 pleomorphic adenoma, 06 Warthin tumour, 25 adenoid cystic carcinoma, 25 mucoepidermoid carcinoma and 02 each basal cell adenocarcinoma and carcinoma ex pleomorphic adenoma) were obtained from different local tertiary care hospitals in Lahore from Jan. 2014 to Sep 2015. After confirming the histologic diagnosis on hematoxylin and eosin stained sections, immunohistochemical expression of EMMPRIN was determined. SPSS version 21.0 was used to determine the association between expression of EMMPRIN in benign, malignant and individual tumors. Chi-square and Fischer Exact tests were applied and p<0.05 was considered to be statistically significant.
    Expression of EMMPRIN in malignant tumors was significantly higher than benign tumors (p< 0.0001). The staining pattern of cells was also significantly associated with type of tumour (p<0.0001). Significant EMMPRIN expression was noted with grades in AdCC (p <0.0001) & MEC (p=0.016).
    The current study concludes that EMMPRIN expression is significantly higher in malignant salivary gland neoplasm's and may help the pathologists for assessing tumor differentiation and malignant potential if added in a panel of other conventional markers.
    Amit Sengupta*, Sanjay Gupta, Arvind Ingle, and Jayant Goda
    HBO has been used as an adjuvant to chemo (CT) or radiotherapy (RT) in cancer; however, in our previous work on survival study in small animal mice model, we reported cancer enhancing effect after cessation of the HBO therapy. The present study was designed to understand the underlying molecular mechanism that may be linked to cancer enhancing phenomenon. Tumor bearing C3H mice were subjected to hyperbaric hyperoxia (1.1 bar & 1.2 bar) therapy consequently for 6 days with a day off in between for 3 weeks. Each session comprised of daily 120 minutes of HBO exposure prior to and after being subjected to RT or CT. Another group was subjected to one, two and three weeks of HBO therapy to observe graded response and severity of DNA damage. We observed proportionate increase in the severity of DNA damage and histone modification in the tumor samples when subjected to longer duration of HBO therapy as compared to tumor control. Thus, we suggest that HBO therapy should be given under highly dose controlled condition and with caution, else dual effect of oxygen toxicity and molecular effects may lead to tumor enhancement or recurrence and/or metastasis.
    Baena-Villamarin C, Beardo P*, Payares JL, and Extramiana J
    Sunitinib is an anti angiogenic agent used in the first line treatment of metastatic renal cell carcinoma (mRCC), which is associated to a high incidence of adverse effects, although neurological adverse effects are uncommon. We describe the case of 76-year-old male with mRRC and severe aortic and mitral valve disease treated with sunitinib, who presented acute confusional syndrome (ACS) during sunitinib treatment without organic condition that, explains his status. After 24 months of sunitinib discontinuation, the patient remains completely recovered from the ACS and showed complete radiological response.
    Khoi Anh Nguyen*, Tu Anh Thai, and Cuong Tri Giang
    Warthins tumor is a salivary gland tumor consisting of epithelial and lymphoid components. The majority of Warthins tumors are benign and malignant transformation is extremely rare. We report a case of malignant transformation of a Warthins tumor of the right parotid gland. The patient had a right parotid tumor and underwent tumor excision. Histopathology after surgery showed malignant transformation of Warthins tumor. On examination, we found a cervical lymph node group VB and Fine Needle Aspiration (FNA) showed metastasis. We decided to perform a total parotidectomy and modified radical right neck dissection for the patient. Then the patient underwent adjuvant radiotherapy. Close follow-up was carried out and 3 months after surgery there was no evidence of recurrence or metastatic neoplasm. Therefore, if there is a parotid tumor which is suspected malignant, we should thoroughly investigate the cervical lymph nodes and consider prophylactic neck dissection although we do not find the susceptive nodes.
    Research Article
    Yasser Mohammed*, Nabila I. El-Desouki, Mohamed A. Basyony, Walied S. Abdo, and Mohammed A. El-Magd*
    This study was conducted to investigate the potential therapeutic effect of Melatonin (Mel) and/or mesenchymal stem cells (MSCs) on diethylnitrosamine (DEN)-induced rat model of HCC. Female mature rats were divided into 5 groups (n = 10/group): normal (Nor) group given saline orally for 20 weeks, and HCC group intraperitoneally injected with 200 mg/kg DEN, in addition to 3 treated groups; HCC + Mel (Mel) group given Mel intraperitoneally 20 mg/kg, twice a week, HCC + MSCs (MSCs) group intravenously injected by 1106 cells/1 ml PBS, and HCC + MSCs (Mel +MSCs) group MSCs were pretreated with 5 M Mel before injection. Rats injected in HCC group showed most deteriorated effect in form of increased mortality and relative liver weight, elevated serum levels of the liver damage enzymes, ALT, AST, and ALP, and the two cancer markers AFP and GGT in addition to increased pre-neoplastic nodules (altered hepatic foci) in liver tissues. Liver tissues of HCC group also exhibited lower level of apoptosis as indicated by decrease in DNA fragmentation, and downregulated expression of the apoptotic genes p53 and caspase 9. Moreover, in this group the expression of inflammation-related genes (IL6 and TGF1) was significantly upregulated. All these deleterious effects induced by DEN were reversed after administration of Mel and/ or MSCs with best improvement for the preconditioned group (MSCs+Mel). These findings reveal a better therapeutic effect for MSCs when preconditioned with Mel before injection and we attribute this beneficial effect, at least in part, to induction of apoptosis and inhibition of inflammation in HCC microenvironment. Therefore, pretreatment with Mel is recommended to enhance the therapeutic potential of MSCs for HCC.
    Special Issue on Lung Cancer China
    Short Communication
    Wanqing Chen*, Rongshou Zheng, Hongmei Zeng and Siwei Zhang
    Cancer is an emerging health issue in China and many other countries of the world. Lung cancer is the first leading cancer diagnosed and cause of cancer death for many years in China with a rapid increasing trend during the past several decades [1,2]. The incidence rate of lung cancer in China was relatively higher and also increasing with a more rapid rate than in western countries. Lots of risk factors such as cigarette smoking, air pollution has been proved as the risk factor of the disease [3-6].
    Review Article
    Jingjing Liu, Ying Cheng*, Hui Li and Shuang Zhang
    Abstract: Small Cell Lung Cancer (SCLC) account for almost 15% of lung cancers, which is strongly associated with cigarette smoking. It has a high propensity for early metastatic dissemination. Since few improvements in treatment effectiveness have been seen over the past 30 years new treatment strategies for improving therapeutic effect were urgently needed. China is the second most populous in the world and has many smokers. The morbidity and mortality of lung cancer are higher than the worldwide average. Because the government didn't take effective measures for smoking cessation, so the morbidity of SCLC has no downward trend. The progresses of studies in SCLC are slowly, such as diagnose, treatment and translational medicine. In recent years, with the emphasis of the society and the public on early diagnosis and early treatment of tumors and the progress of medical diagnosis technology, Chinese scholars have made many attempts in the treatment and research of SCLC.
    Xiu-Yi Zhi1*, Xiao-Nong Zou2, Mu Hu1, Yuan Jiang3 and You-lin Qiao4
    Abstract: In recent decades the age-specific mortalities of lung cancer in China have been increased to 9 times in men and women and it become one of the most important public health issues. The high prevalence of smoking in men and more than 70% of nonsmokers, both men and women, could be the biggest contributable factor for those consequences. While the abundant evidence on the health risks of exposure to smoking were available in both international and domestic studies the awareness on the health hazards from tobacco use were quit low in Chinese peoples, even in the health providers. Changes in the contents and the process of the tobacco products in Chinese tobacco product markets were accompanied by increased numbers of the lung cancer cases, increased adenocarcinoma and decreased squamous cell carcinoma of the lung, rather than reducing the overall lung cancer cases. Those suggested that comprehensive smoking-free policy should be implemented in all public places and the process of smoking-free legislation should put forward to create the legal environment and provide effective protection for reducing the incidence of lung cancer. Popularized health education should be also enhanced to raise the public awareness on smoking hazards.
  • Current Issue Highlights
  • BRAT1 was originally identified as a BRCA1 interacting protein [1], however, subsequent studies showed that it also binds to ATM, DNA-PK, and SMC1,

    Mechanisms of detecting and repairing damaged DNA are conserved and controlled through the DNA damage response (DDR).

    JSciMed Central Peer-reviewed Open Access Journals
    10120 S Eastern Ave, Henderson,
    Nevada 89052, USA
    Tel: (702)-751-7806
    Toll free number: 1-800-762-9856
    Fax: (844)-572-4633 (844-JSCIMED)
    E-mail: cancerbiology@jscimedcentral.com
    1455 Frazee Road, Suite 570
    San Diego, California 92108, USA
    Tel: (619)-373-8720
    Toll free number: 1-800-762-9856
    Fax: (844)-572-4633 (844-JSCIMED)
    E-mail: cancerbiology@jscimedcentral.com
    About      |      Journals      |      Open Access      |      Special Issue Proposals      |      Guidelines      |      Submit Manuscript      |      Contacts
    Copyright © 2016 JSciMed Central All Rights Reserved
    Creative Commons Licence Open Access Publication by JSciMed Central is licensed under a Creative Commons Attribution 4.0 International License.
    Based on a work at https://jscimedcentral.com/. Permissions beyond the scope of this license may be available at https://creativecommons.org/.